Is ReShape Lifesciences Stock a Good Investment?
ReShape Lifesciences Investment Advice | RSLS |
- Examine ReShape Lifesciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research ReShape Lifesciences' leadership team and their track record. Good management can help ReShape Lifesciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact ReShape Lifesciences' business and its evolving consumer preferences.
- Compare ReShape Lifesciences' performance and market position to its competitors. Analyze how ReShape Lifesciences is positioned in terms of product offerings, innovation, and market share.
- Check if ReShape Lifesciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about ReShape Lifesciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in ReShape Lifesciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if ReShape Lifesciences is a good investment.
Sell | Buy |
Hold
Market Performance | Modest | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Very regressive towards the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine ReShape Lifesciences Stock
Researching ReShape Lifesciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was at this time reported as 9.24. The company recorded earning per share (EPS) of 264.12. ReShape Lifesciences last dividend was issued on the 25th of July 2019. The entity had 1:25 split on the 9th of May 2025.
To determine if ReShape Lifesciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ReShape Lifesciences' research are outlined below:
| ReShape Lifesciences is way too risky over 90 days horizon | |
| ReShape Lifesciences appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 8.01 M. Net Loss for the year was (7.13 M) with profit before overhead, payroll, taxes, and interest of 4.57 M. | |
| ReShape Lifesciences currently holds about 11.49 M in cash with (4.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51. | |
| ReShape Lifesciences has a frail financial position based on the latest SEC disclosures |
ReShape Lifesciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ReShape Lifesciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ReShape Lifesciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 23rd of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
ReShape Lifesciences' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.82 M.ReShape Lifesciences' profitablity analysis
The company has Profit Margin (PM) of (0.48) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.65) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.65.Determining ReShape Lifesciences' profitability involves analyzing its financial statements and using various financial metrics to determine if ReShape Lifesciences is a good buy. For example, gross profit margin measures ReShape Lifesciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ReShape Lifesciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in ReShape Lifesciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ReShape Lifesciences. Check ReShape Lifesciences' Beneish M Score to see the likelihood of ReShape Lifesciences' management manipulating its earnings.
Basic technical analysis of ReShape Stock
As of the 29th of June, ReShape Lifesciences holds the Semi Deviation of 14.95, market risk adjusted performance of 0.7145, and Risk Adjusted Performance of 0.1155. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of ReShape Lifesciences, as well as the relationship between them. Please check ReShape Lifesciences information ratio and downside variance to decide if ReShape Lifesciences is priced some-what accurately, providing market reflects its current price of 2.44 per share. Please also confirm ReShape Lifesciences total risk alpha, which is currently at 1.69 to check out the company can sustain itself at a future point.ReShape Lifesciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ReShape Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on ReShape Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ReShape Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ReShape Lifesciences' Outstanding Corporate Bonds
ReShape Lifesciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ReShape Lifesciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ReShape bonds can be classified according to their maturity, which is the date when ReShape Lifesciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand ReShape Lifesciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing ReShape Lifesciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1155 | |||
| Market Risk Adjusted Performance | 0.7145 | |||
| Mean Deviation | 18.02 | |||
| Semi Deviation | 14.95 | |||
| Downside Deviation | 16.48 | |||
| Coefficient Of Variation | 1553.45 | |||
| Standard Deviation | 46.97 | |||
| Variance | 2205.95 | |||
| Information Ratio | 0.0632 | |||
| Jensen Alpha | 2.81 | |||
| Total Risk Alpha | 1.69 | |||
| Sortino Ratio | 0.1801 | |||
| Treynor Ratio | 0.7045 | |||
| Maximum Drawdown | 411.9 | |||
| Value At Risk | (20.49) | |||
| Potential Upside | 35.81 | |||
| Downside Variance | 271.47 | |||
| Semi Variance | 223.39 | |||
| Expected Short fall | (32.40) | |||
| Skewness | 6.14 | |||
| Kurtosis | 44.27 |
| Risk Adjusted Performance | 0.1155 | |||
| Market Risk Adjusted Performance | 0.7145 | |||
| Mean Deviation | 18.02 | |||
| Semi Deviation | 14.95 | |||
| Downside Deviation | 16.48 | |||
| Coefficient Of Variation | 1553.45 | |||
| Standard Deviation | 46.97 | |||
| Variance | 2205.95 | |||
| Information Ratio | 0.0632 | |||
| Jensen Alpha | 2.81 | |||
| Total Risk Alpha | 1.69 | |||
| Sortino Ratio | 0.1801 | |||
| Treynor Ratio | 0.7045 | |||
| Maximum Drawdown | 411.9 | |||
| Value At Risk | (20.49) | |||
| Potential Upside | 35.81 | |||
| Downside Variance | 271.47 | |||
| Semi Variance | 223.39 | |||
| Expected Short fall | (32.40) | |||
| Skewness | 6.14 | |||
| Kurtosis | 44.27 |
Consider ReShape Lifesciences' intraday indicators
ReShape Lifesciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ReShape Lifesciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ReShape Lifesciences time-series forecasting models is one of many ReShape Lifesciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ReShape Lifesciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
ReShape Stock media impact
There is far too much social signal, news, headlines, and media speculation about ReShape Lifesciences that are available to investors today. This information is accessible both publicly - through ReShape Lifesciences' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of ReShape-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of ReShape Lifesciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ReShape Lifesciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ReShape Lifesciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ReShape Lifesciences alpha.
ReShape Lifesciences Corporate Management
| MBA DVM | VP Officer | Profile | |
| Al Diaz | Vice RD | Profile | |
| DVM DVM | VP Officer | Profile | |
| Thomas Stankovich | Chief Officer | Profile | |
| Jody Dahlman | Director Communications | Profile | |
| Katherine Tweden | CoFounder | Profile |
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.